https://www.selleckchem.com/products/blz945.html
Patients converting to secondary progressive MS were older, and had higher EDSS scores and greater brain lesion volumes at baseline, but did not need additional alemtuzumab or other therapies. The 6-year conversion rate to secondary progressive MS was low for alemtuzumab-treated patients, supporting further study of the role alemtuzumab may play in reducing risk of secondary progression. NCT00530348, NCT00548405, NCT00930553. The 6-year conversion rate to secondary progressive MS was low for alemtuzumab-treated patients, supporting furth